Grifols, S.A. (GRFS): Price and Financial Metrics
GRFS Price/Volume Stats
| Current price | $6.28 | 52-week high | $12.15 |
| Prev. close | $6.54 | 52-week low | $5.30 |
| Day low | $6.27 | Volume | 1,236,900 |
| Day high | $6.46 | Avg. volume | 2,967,311 |
| 50-day MA | $7.16 | Dividend yield | N/A |
| 200-day MA | $8.81 | Market Cap | 4.32B |
GRFS Stock Price Chart Interactive Chart >
Grifols, S.A. (GRFS) Company Bio
Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories. (Source:Wikipedia)
Latest GRFS News From Around the Web
Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.
GRFS or ZTS: Which Is the Better Value Stock Right Now?GRFS vs. ZTS: Which Stock Is the Better Value Option? |
Are You Looking for a Top Momentum Pick? Why Grifols (GRFS) is a Great ChoiceDoes Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
5 Best Breakout Stocks to Invest in for Attractive ReturnsGrifols (GRFS), Denison Mine Corp (DNN), NGL Energy Partners (NGL), Macatawa Bank (MCBC) and Navient (NAVI) have been selected as the breakout stocks for today. |
GRFS vs. ZTS: Which Stock Is the Better Value Option?GRFS vs. ZTS: Which Stock Is the Better Value Option? |
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsGrifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment. |
GRFS Price Returns
| 1-mo | -7.37% |
| 3-mo | -7.10% |
| 6-mo | -20.61% |
| 1-year | -17.04% |
| 3-year | -64.61% |
| 5-year | -64.45% |
| YTD | -45.67% |
| 2023 | 36.00% |
| 2022 | -24.31% |
| 2021 | -37.78% |
| 2020 | -20.15% |
| 2019 | 28.71% |
Continue Researching GRFS
Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...